Shares in Biogen (Nasdaq: BIIB) slumped by 6% during Tuesday morning’s trading in New York.
The US biotech major had just presented its financial results for the fourth quarter and full year for 2023, as well as giving its estimates for the year ahead.
Biogen’s fourth quarter revenue of $2.39 billion was 6% lower than the same period of 2022 and missed analysts’ modest expectations for a figure of $2.47 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze